Gilead (GILD) Q4 FY25 earnings call

Gilead closed FY25 with strong commercial execution, particularly in HIV and Livdelzi, driving total product sales above guidance. The company is entering 2026 with a robust pipeline, targeting four new commercial launches and five Phase III readouts across its core therapeutic areas, while maintaining expense discipline and a proactive approach to business development. This positions Gilead for continued growth with no major product LOEs until 2036.